Ankylosing Spondylitis, Endothelial Dysfunction, Inflammatory Disease Activity, Psoriatic Arthritis, Rheumatoid Arthritis
Conditions
Keywords
Endothelial dysfunction, Bone and cartilage markers, Inflammatory disease activity, Rheumatoid arthritis, Psoriatic arthritis, Ankylosing Spondylitis
Brief summary
The aim of this study is to examine the associations between inflammatory disease activity and endothelial function in rheumatoid arthritis (RA) and spondyloarthritis patients treated with methotrexate and Tumor Necrosis Factor alpha (TNFalpha)inhibitor in combination or methotrexate or TNFalpha-inhibitor alone. Further, to look for improvement in endothelial function, and decrease in bone and cartilage destruction during treatment with the combination therapy of TNFalpha-inhibitor and methotrexate in RA and Psoriatic Arthritis (PSA) patients. Last, examine the TNFalpha inhibitors influence on endothelial function and levels of bone and cartilage markers in patients with Ankylosing Spondylitis (AS).
Interventions
None listed
Sponsors
Abbott
Revmatismesykehuset AS
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Males and females 18-80 years * Able and willing to give written informed consent, and to comply with the requirements of the study protocol. * Fulfilling the ACR 1987 revised diagnostic criteria for the diagnosis rheumatoid arthritis, or the diagnostic criteria by Moll and Wright for the diagnosis psoriatic arthritis, or the modified New York diagnostic criteria for ankylosing spondylitis. * Clinical indication for starting treatment with methotrexate, TNFalpha- inhibitor or combination therapy. * Use of reliable method of contraception for women with childbearing potential.
Exclusion criteria
* Lack of cooperativity * Positive serology for hepatitis B or C * History of positive HIV status. * History of tuberculosis or untreated tuberculosis. * PPD more than 15 mm in previously BCG immunized subjects. PPD 6 mm or more if not previously BCG immunized. * Histoplasmosis or Listeriosis * Persistent or recurrent infections * Any inflammatory disease of permanence not related to RA, PSA or AS. * Pregnancy or breast-feeding. * Use of prednisolone more than 10 mg daily for 2 weeks at inclusion. * Use of TNFalpha-inhibitor the last 4 weeks. * History of cancer. * Uncontrolled diabetes. * Congestive heart failure (Nyha 3-4) * Recent stroke (within 3 months) * Previous diagnosis or signs of central nervous system demyelinating disease. * Previously diagnosed immunodeficiency.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To examine the association between inflammatory disease activity and endothelial function in RA and spondyloarthritis patients treated with methotrexate and TNFalpha-inhibitor in combination or methotrexate or TNFalpha-inhibitor alone | Baseline (before treatment starts), 6 weeks and 6 months after starting treatment |
Secondary
| Measure | Time frame |
|---|---|
| CRP (C-reactive protein) | Baseline (before starting treatment), 6 weeks, 6 months after starting treatment |
| DAS28 (Disease activity score) | Baseline (before starting treatment), 6 weeks, 6 months after starting treatment |
| COMP (cartilage oligomeric matrix protein 1) | Baseline (before starting treatment), 6 weeks, 6 months after starting treatment |
| IL-6 (interleukin 6) | Baseline (before starting treatment), 6 weeks, 6 months after starting treatment |
| s-RAGE (Receptor of Advanced Glycation End products) | Baseline (before starting treatment), 6 weeks, 6 months after starting treatment |
Countries
Norway
Outcome results
None listed